<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179137</url>
  </required_header>
  <id_info>
    <org_study_id>2181-198-03</org_study_id>
    <nct_id>NCT03179137</nct_id>
  </id_info>
  <brief_title>Mitochondrial Bioenergetics and Role in Cellular Damage in Ischemic Myocardium</brief_title>
  <official_title>Pathophysiological Mechanisms Elicited by Ischemia and Metabolic Co-morbidities in Myocardium of Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Split, School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Split, School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac ischemia is a common pathological condition, known to elicit multiple pathological
      processes at the cellular level. One of the most affected is thought to be cellular
      metabolism, key for the adequate cardiac function. The aim is to study mitochondrial
      bioenergetic function, interaction with other cellular systems and influence of several
      co-morbidities in myocardium of the affected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery disease, one of the most common pathologies in the developed world, causes
      hypoperfusion of myocardial tissue, usually evident by the presence of anginal pain. This
      myocardial ischemia elicits alterations in normal cardiomyocyte physiology, which gradually
      deteriorate cellular function, affecting the performance of the entire organ. The condition
      is frequently further complicated (and aggravated) by the presence of various co-morbidities,
      such as diabetes mellitus. The primary aim of this study is to investigate the cardiomyocyte
      bioenergetics and the consequences of potentially reduced mitochondrial metabolic function in
      ischemic heart, and evaluate the potential contribution of other conditions, primarily ones
      affecting metabolic homeostasis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial oxygen consumption (rate of oxygen consumption per milligram of left ventricular tissue)</measure>
    <time_frame>2016-2020</time_frame>
    <description>Mitochondrial respiration in nmol O2/minute/mg of tissue weight will be measured as an indicator of mitochondrial ATP production capacity, using different metabolic substrates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial production of reactive oxygen species</measure>
    <time_frame>2016-2020</time_frame>
    <description>Myocardial production of reactive oxygen species will be measured using electron paramagnetic resonance and fluorometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-cardiolipin antibodies in the blood of patients with symptoms of cardiac ischemia</measure>
    <time_frame>2016-2020</time_frame>
    <description>Anticardiolipin antibodies assessed in venous blood of patients with angina pectoris undergoing coronary angiography</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Mitochondrial Metabolism Disorders</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <description>Patients with therapy prescribed independent of the study</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human myocardial tissue, atrial and ventricular; Venous blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hemodynamically stable patients with coronary artery disease diagnosed with angiography
        with indication for coronary artery bypass grafting surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary artery disease

          -  Indication for coronary artery bypass grafting surgery

        Exclusion Criteria:

          -  Emergency patients

          -  Patients with LV ejection fraction (LVEF) below 30%

          -  Patients with severe renal, hepatic or pulmonary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>School of Medicine, University of Split</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03179137/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

